Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593759 | SCV000707365 | uncertain significance | not provided | 2017-04-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000593759 | SCV001060323 | likely benign | not provided | 2024-09-22 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000593759 | SCV001791588 | uncertain significance | not provided | 2019-11-04 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect |
Ambry Genetics | RCV004024811 | SCV004957107 | likely benign | Inborn genetic diseases | 2023-11-21 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003980102 | SCV004791990 | likely benign | SPTBN2-related disorder | 2022-05-31 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |